Teriflunomide (Aubagio): MS Clinical Trials
9 active trials · 2 recruiting
9 active multiple sclerosis clinical trials involve Teriflunomide (Aubagio), 2 currently recruiting. The list is matched on the interventions registered at ClinicalTrials.gov, so it includes head-to-head comparisons and studies where this therapy is the comparator as well as the treatment under test.
Trial results are not treatment advice: whether a therapy is right for you depends on your type of MS, disease activity and history, which is a conversation for your neurologist.
Active Teriflunomide (Aubagio) MS trials
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
ofatumumab · glatiramer acetate
800 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
By invitation only
Relationship Between Oral DMT Burden and Adherence in MS
Sponsor: Monash University
Cladribine · Dimethyl fumarate
323 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
23 states1011 participantsDetails ›
Closed to new patientsPhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Teriflunomide
13 states751 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
27 states1001 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Teriflunomide
23 states746 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsNA
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sponsor: Johns Hopkins University
Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…
28 states900 participantsDetails ›
MS trials by therapy
Exercise and rehabilitation (81)Ocrelizumab (Ocrevus) (34)Ofatumumab (Kesimpta) (18)Diet and nutrition (12)Fingolimod (Gilenya) (8)Ublituximab (Briumvi) (7)Cladribine (Mavenclad) (7)Rituximab (6)Ozanimod (Zeposia) (6)Dimethyl fumarate (Tecfidera) (6)Interferon beta (5)Fenebrutinib (5)Stem cell therapy (aHSCT and MSC) (5)Natalizumab (Tysabri) (4)Siponimod (Mayzent) (4)Remibrutinib (4)CAR-T cell therapy (4)Alemtuzumab (Lemtrada) (3)Glatiramer acetate (Copaxone) (3)Frexalimab (3)Metformin (3)Cannabis and cannabinoids (3)
